 |
市場調查報告書
商品編碼
1358082
病毒性結膜炎治療藥物市場：依藥物類別、按病毒類型、按配銷通路、按地區Viral Conjunctivitis Drugs Market, By Drug Class, By Virus Type (Adenovirus, Enterovirus, Others ), By Distribution Channel, By Geography |
||||||
預計2023年，全球病毒性結膜炎治療藥物市值為3.225億美元，預計在預測期內（2023-2030年）年複合成長率為5.1%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2022年 | 2023年市場規模 | 3.225 億美元 |
| 實績資料 | 2018-2021 | 預測期 | 2023-2030 |
| 預測期年複合成長率 | 5.10% | 2030年市場規模預測 | 4.567 億美元 |
病毒性結膜炎是由多種病毒引起的急性結膜感染疾病，包括腺病毒和單純皰疹病毒。病毒性結膜炎佔感染性結膜炎的大部分，佔病例的75%。病毒性結膜炎的特徵包括發紅、紅血管、眼睛分泌物、疼痛和畏光。由腺病毒群引起的病毒性結膜炎稱為流行性角結膜炎（EKC）。這群腺病毒有不同的血清型，也可能引起咽結膜熱和特異性濾泡性結膜炎。根據《美國眼科學會：2021》發表的一篇論文，腺病毒性結膜炎是成年人中最常見的眼部感染疾病類型。腺病毒結膜炎具有高度傳染性，引起感染的病毒可以在檯面和其他表面上存活數週。
市場動態
市場參與者正在進行各種無機活動，例如公司收購、產品核可和其他活動，預計這些活動將在預測期內推動全球病毒性結膜炎治療藥物市場的成長。例如，2020 年 2 月，Bausch Health Companies Inc. 和製藥公司的全資子公司 Eton Pharmaceuticals, Inc. 宣布已獲得 Eton Pharmaceuticals 在臨床實驗眼藥水 EM-100 的美國權利。如果核准，該眼藥水將成為第一種用於治療與結膜炎相關的眼睛搔癢的非處方（OTC）不含防腐劑的眼藥水。
此外，2020年7月，全球眼科護理領導者愛爾康宣布，Pataday Once Daily Relief Extra Strength（鹽酸奧洛他定眼用溶液0.7%）（原處方為Pazeo）已獲得美國食品藥物管理局批准，作為過度治療藥物。美國非處方藥（FDA）宣布已獲核准。 Pataday Once Daily Relief Extra Strength 是第一個也是唯一一個每天一次的滴眼液，無需處方箋即可提供 24 小時緩解眼睛瘙癢的效果。過敏是美國慢性病的第六大原因，非處方藥零售額約 27 億美元。
本研究的主要特點
- 該報告對全球病毒性結膜炎治療藥物市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030年）的市場規模和年複合成長率(CAGR)。它揭示了各個細分市場的潛在商機，並說明了市場有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
- 它根據公司亮點、產品系列、主要亮點、績效和策略等參數，介紹了全球病毒性結膜炎治療藥物市場的主要企業。
- 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
- 全球病毒性結膜炎治療藥物市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
- 相關人員可以透過用於分析全球病毒性結膜炎治療藥物市場的各種策略矩陣來促進決策。
目錄
第1章 調查目的和假設
- 這項研究的目的
- 假設
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章 市場動態、法規及趨勢分析
- 市場動態
- 促進因素
- 抑制因素
- 市場機會
- 影響分析
- 最近測試啟動
- 流行病學
- 合併、收購和合作
- 法規場景
- 主要進展
- PEST分析
第4章 全球病毒性結膜炎治療藥物市場－新型冠狀病毒感染疾病（COVID-19）影響分析
- 經濟影響
- 新型冠狀病毒感染疾病（COVID-19）的流行病學
- 對需求和供給的影響
第5章 全球病毒性結膜炎治療藥物市場：依藥物類別，2018-2030
- 抗生素
- 人工淚液
- 減充血劑
- 抗組織胺藥
- NSAIDs
- 抗病毒藥物
- 其他
第6章 全球病毒性結膜炎治療藥物市場：依病毒類型，2018-2030
- 腺病毒
- 腸病毒
- 其他（單純皰疹病毒（HSV）等）
第7章 全球病毒性結膜炎治療藥物市場：依配銷通路，2018-2030
- 醫院藥房
- 零售藥房
- 網路藥房
第8章 全球病毒性結膜炎治療藥物市場：按地區分類，2018-2030年
- 北美洲
- 美國
- 加拿大
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 中東
- GCC
- 以色列
- 其他中東地區
- 非洲
- 北非
- 中部非洲
- 南非
第9章 競爭形勢
- 公司簡介
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Bausch Health Companies Inc.
- Panoptes Pharma Ges.mbH
- NovaBay Pharmaceuticals, Inc.
- Nicox, NanoViricides Inc.
- Novartis International AG
- Pfizer Inc.
- Johnson &Johnson
- GlaxoSmithKline Plc.
- Santen Pharmaceutical Co.Ltd.
- Alcon
- Okogen Inc.
第10章 章
- 參考
- 調查方法
The global viral conjunctivitis drugs market is estimated to be valued at US$ 322.5 million in 2023 and is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 322.5 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 5.10% | 2030 Value Projection: | US$ 456.7 Mn |
Viral conjunctivitis is an acute conjunctival infection that is caused by various viruses, such adenovirus, herpes simplex virus, etc. Viral conjunctivitis is responsible for the majority of infectious conjunctivitis, accounting for up to 75% of cases. Characteristics of ocular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia, etc. Viral conjunctivitis that is caused by a group of adenoviruses is called epidemic keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2021, adenoviral conjunctivitis is the most common type of eye infection in the adult population. Adenoviral conjunctivitis is highly contagious, as the virus causing the infection can survive on a countertop or a similar surface for several weeks.
Market Dynamics
Market players are engaged in various inorganic activities such as acquisitions of companies, product approval, and others, which in turn is expected to drive growth of the global viral conjunctivitis drugs market over the forecast period. For instance, on February 2020, Bausch Health Companies Inc.'s wholly owned subsidiary, Eton Pharmaceuticals, Inc., a pharmaceutical company, announced that they had acquired the U.S. rights to Eton Pharmaceuticals' EM-100, an investigational eye drop that, if approved, would be the first over-the-counter (OTC) preservative-free formulation eye drop to be used for the treatment of ocular itching associated with conjunctivitis.
Furthermore, in July 2020, Alcon, the global leader in eye care, announced that Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo, had been approved by the U.S. Food and Drug Administration (FDA) for sale over-the-counter (OTC) in the U.S. Pataday Once Daily Relief Extra Strength is the first and only once-daily eye allergy itch drop offering a full 24 hours of relief without a prescription. Allergies are the sixth-leading cause of chronic illness in the U.S., generating approximately US$ 2.7 billion in OTC retail sales.
Key features of the study:
- This report provides an in-depth analysis of the global viral conjunctivitis drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global viral conjunctivitis drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., Santen Pharmaceutical Co.Ltd., Alcon and Okogen Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral conjunctivitis drugs market.
Detailed Segmentation:
- By Drug Class:
- Antibiotics
- Artificial tears
- Decongestants
- Anti-histamines
- NSAIDS
- Anti-Viral drugs
- Others (Steroids, etc.)
- By Viral Type:
- Adenovirus
- Enterovirus
- Others (Herpes Simplex Virus (HSV), etc.)
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Bausch Health Companies Inc.
- Panoptes Pharma Ges.m.b.H
- NovaBay Pharmaceuticals, Inc.
- Nicox, NanoViricides Inc.
- Novartis International AG
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline Plc.
- Santen Pharmaceutical Co.Ltd.
- Alcon
- Okogen Inc.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Virus Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Viral Conjunctivitis Drugs Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Artificial tears
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Decongestants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Anti-histamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- NSAIDS
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Anti-Viral drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030, (US$ Mn)
- Segment Trends
6. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Adenovirus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Enterovirus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Others (Herpes Simplex Virus (HSV), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
7. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
8. Global Viral Conjunctivitis Drugs Market, By Region, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2018-2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bausch Health Companies Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Panoptes Pharma Ges.m.b.H
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- NovaBay Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Nicox, NanoViricides Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GlaxoSmithKline Plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Santen Pharmaceutical Co.Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Alcon
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Okogen Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
10. Section
- References
- Research Methodology
- About us and Sales Contact
